



CASE
COMPREHENSIVE
CANCER CENTER



American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2020

Friday, May 29 – Sunday, May 31

<https://meetings.asco.org/am/virtual-program>

Cancer Center Members indicated in **BOLD**

Plenary Session

[\(LBA2\) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group \(E2108\).](#)

Breast Cancer—Local/Regional/Adjuvant – Local-Regional Therapy

Sunday, May 31, 2020, 1:00 PM ET

Authors: Seema Ahsan Khan, Fengmin Zhao, Lawrence J. Solin, Lori J. Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B. Julian, Barbara A. Pockaj, Christine A Lee, Wajeeha Razaq, Joseph A. Sparano, Gildy V Babiera, Irene Ang Dy, Sarika Jain, **Paula Silverman**, Carla Fisher, Amye Juliet Tevaarwerk, Lynne I. Wagner, George W. Sledge; Northwestern Memorial Hospital, Chicago, IL; Dana–Farber Cancer Institute, Malden, MA; Albert Einstein Medical Center, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; McGill University, Jewish General Hospital Segal Cancer Centre, Montréal, QC, Canada; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA; Mayo Clinic, Phoenix, AZ; Swedish Medical Center, Seattle, WA; NSABP Foundation and Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; University of Texas MD Anderson Cancer Center, Houston, TX; St. Luke's-Roosevelt Hospital, Effingham, IL; Northwestern University Division of Hematology/Oncology, Chicago, IL; University Hospitals Case Medical Center, Cleveland, OH; Indiana University School of Medicine, Indianapolis, IN; University of Wisconsin Carbone Cancer Center, Madison, WI; Wake Forest University Health Sciences, Winston Salem, NC; Stanford University School of Medicine, Stanford, CA

Clinical Science Symposium

MET Mutations: The Meat of the Matter

[\(9510\) Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer \(NSCLC\) patients with MET amplification/exon 14 deletion \(METamp/Ex14Δ\).](#)

Authors: D. Ross Camidge, Filip Janku, Alejandro Martinez-Bueno, Daniel V.T. Catenacci, Jeeyun Lee, Se-Hoon Lee, **Afshin Dowlati**, Kristoffer Staal Rohrberg, Alejandro Navarro, Yong Wha Moon, Mark M. Awad, Rebecca Suk Heist, Thomas Tuxen Poulsen, Arielle Yablonovitch, Lindsay Fosler, Helle Rudbaek, Frank Nygaard, Debra L. Wood, Rita P. Dalal, Enriqueta Felip; Medical Oncology Department, University of Colorado, Aurora, CO; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX; Instituto Oncológico Dr Rosell, Hospital Universitario Quirón Dexeus, Barcelona, Spain; University of Chicago Medical Center and Biological Sciences, Chicago, IL; Samsung Medical Center, Seoul, South Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospital of

Cancer Center members indicated in **BOLD**

Copenhagen Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; CHA Bundang Medical Center, CHA University, Bundang, South Korea; Massachusetts General Hospital, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Symphogen A/S, Ballerup, Denmark; Bioinformatics, Guardant Health, Redwood City, CA; Guardant Health, Redwood City, CA; Nadler Pharma Associates, LLC, Randolph, NJ; Formerly Eli Lilly and Company, Bridgewater, NJ; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Oral Abstract Sessions

[\(1002\) TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response \(DDR\) pathway genes \(Olaparib Expanded\).](#)

Oral Abstract Session: Breast Cancer—Metastatic

Authors: Nadine M. Tung, Mark E. Robson, Steffen Ventz, Cesar Augusto Santa-Maria, Paul Kelly Marcom, Rita Nanda, Payal D Shah, Tarah Jean Ballinger, Eddy Shih-Hsin Yang, Michelle E. Melisko, Adam Brufsky, Shaveta Vinayak, Michelle Demeo, Colby Jenkins, Susan M. Domchek, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy Ellen Garber, Translational Breast Cancer Research Consortium; Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Brookline, MA; Northwestern University Feinberg School of Medicine, Chicago, IL; Duke University Medical Center, Durham, NC; The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA

[\(6003\) A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.](#)

Oral Abstract Session: Gynecologic Cancer

Authors: Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Gillette Cloven, Carolyn Muller, David Bender, Richard G. Moore, David Paul Michelin, **Steven E. Waggoner**, Melissa Ann Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman; Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD; University of Washington School of Medicine, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology, Ft. Worth, TX; University of New Mexico, Albuquerque, NM; University of Iowa, Iowa City, IA; University of Rochester Medical Center, Rochester, NY; Cancer Research Consortium of West Michigan, Grand Rapids, MI; Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH; University of Minnesota, Minneapolis, MN; Saitama Medical University International Medical Center, Hidaka, Japan; Sutter Medical Group, Sacramento, CA; University of Hawaii, Honolulu, HI; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Kaiser Permanente Northern California, San Francisco, CA

[\(9000\) Randomized phase II clinical trial of cisplatin/carboplatin and etoposide \(CE\) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer \(ES-SCLC\): ECOG-ACRIN EA5161.](#)

Oral Abstract Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Authors: Ticiana Leal, Yating Wang, **Afshin Dowlati**, DeQuincy Andrew Lewis, Yuanbin Chen, Amit

Cancer Center members indicated in **BOLD**

Ramesh Mohindra, Mohammad Razaq, Harish G. Ahuja, Jijun Liu, David M. King, Christopher Joseph Sumey, Suresh S. Ramalingam; University of Wisconsin Carbone Cancer Center, Madison, WI; ECOG-ACRIN Biostatistics Center, Boston, MA; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Randolph Cancer Ctr, Asheboro, NC; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI; Ramesh K Mohindra MD PC, Franklin, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Aspirus Reg Cancer Ctr, Wausau, WI; Illinois Cancer Care, Peoria, IL; Minnesota Onc, St Paul, MN; Univ of Colorado, Aurora, CO; Winship Cancer Institute, Emory University Hospital, Atlanta, GA

Poster Discussion Sessions

[\(5019\) Phase II neoadjuvant \(N-\) gemcitabine \(G\) and pembrolizumab \(P\) for locally advanced urothelial cancer \(laUC\): Interim results from the cisplatin \(C\)-ineligible cohort of GU14-188.](#)

Poster Discussion Session: Genitourinary Cancer—Kidney and Bladder

Authors: Hristos Z. Kaimakliotis, Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L Smith, Radhika Walling, Timothy A. Masterson, Adam C Calaway, Michael O. Koch, Elizabeth Sonderman, **Pingfu Fu**, Gordon Goolamier, Cheryl Eitman, **Lee Evan Ponsky**, **Christopher J. Hoimes**; Indiana University Simon Cancer Center, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Washington University in St. Louis School of Medicine, St. Louis, MO; Washington University School of Medicine, St Louis, MO; Community Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Seidman Cancer Center at University Hospitals Cleveland Medical Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Duke Cancer Institute, Durham, NC

[\(8520\) A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.](#)

Poster Discussion Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Authors: Elizabeth O'Donnell, Andrew Jenho Yee, Omar Nadeem, Brea Lipe, Jacob Laubach, **Ehsan Malek**, Andrew Branagan, Robb S. Friedman, Paul G. Richardson, Ajay K. Nooka, Noopur S. Raje; Massachusetts General Hospital Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Rochester, Rochester, NY; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH; Beth Israel Deaconess Cancer Ctr Needham, Newton, MA; Dana Farber Cancer Institute, Boston, MA; Winship Cancer Institute of Emory University, Atlanta, GA

Poster Sessions

[\(528\) Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer.](#)

Breast Cancer—Local/Regional/Adjuvant – Adjuvant Therapy

Authors: **Cynthia Owusu**, Seunghee P Margevicius, Heidi D. Klepin, Charles L. Vogel, Asrar Alahmadi, Sowjanya Vuyyala, Adam Brufsky; Case Western Reserve University School of Medicine, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC; Sylvester At Deerfield Beach, Deerfield Beach, FL; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA

[\(572\) Impact of axillary lymph node dissection \(ALND\) on survival in patients with ypN1 breast cancer that receive regional nodal irradiation \(RNI\): A national cancer database \(NCDB\) analysis.](#)

Cancer Center members indicated in **BOLD**

Breast Cancer—Local/Regional/Adjuvant – Local-Regional Therapy

Authors: Michael Kharouta, Nicholas Damico, Eleanor Elizabeth Harris, **Janice A. Lyons**; University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH

[\(3583\) Results of a completed phase I trial of CBL0137 administered intravenously \(IV\) to patients \(Pts\) with advanced solid tumors.](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology - New Targets and New Technologies (non-IO)

Authors: John Sarantopoulos, Devalingam Mahalingam, Neelesh Sharma, Renuka V. Iyer, Wen Wee Ma, Manmeet Singh Ahluwalia, Saramarie Johnson, Andrei Purmal, Polina Shpigotskaya, Ann Hards, Andrey Leonov, Katerina Gurova, Andrei Gudkov, Kristina Zakurdaeva, Langdon L. Miller, **Afshin Dowlati**; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX; Northwestern University, Chicago, IL; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Incuron, Inc, Buffalo, NY; Incuron, LLC, Moscow, Russian Federation

[\(3634\) A randomized, controlled trial of structured palliative care versus standard supportive care for patients enrolled on phase I clinical trials.](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Other

Authors: **Michelle Elizabeth Treasure**, **Barbara J. Daly**, **PingFu Fu**, Shufen Cao, Neal J. Meropol, **Afshin Dowlati**; Cleveland Clinic Foundation, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Flatiron Health, New York, NY and Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

[\(4062\) Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer \(mCRC\).](#)

Gastrointestinal Cancer—Colorectal and Anal – Biologic Correlates

Authors: Patrick M Boland, Jason Muhitch, Scott I Abrams, Orla Maguire, Hans Minderman, **David Lawrence Bajor**, Joel N. Saltzman, Katy Wang, Alan Hutson, Sarbajit Mukherjee, Renuka V. Iyer, Pawel Kalinski, Christos Fountzilas; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Roswell Park Cancer Institute, Buffalo, NY; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY

[\(4623\) Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer

Authors: Fang Liu, Matthew Mirsky, Sulin Wu, **Pingfu Fu**, Shufen Cao, John Shanahan, Ravi Kumar Kyasaram, Prantesh Jain, **Jeffrey Hardacre**, John Brian Ammori, **Jordan Michael Winter**, **David Lawrence Bajor**; University Hospital, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Department of Biostatistics and Epidemiology, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals-Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Cancer Center members indicated in **BOLD**

[\(4643\) A pilot study to determine the feasibility of a customized low glycemic load diet in patients with stage I-III colorectal cancer.](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Other GI Cancer
Authors: **Michelle Elizabeth Treasure**, Alicia Thomas, Stephen Ganocy, Augustine Hong, **Smitha S. Krishnamurthi**, **David Lawrence Bajor**, **Nathan A. Berger**, Neal J. Meropol; Cleveland Clinic Foundation, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Cleveland Clinic Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH; Flatiron Health, New York, NY and Case Comprehensive Cancer Center, Cleveland, OH

[\(5047\) Phase Ib/II neoadjuvant \(N-\) pembrolizumab \(P\) and chemotherapy for locally advanced urothelial cancer \(laUC\): Final results from the cisplatin \(C\)- eligible cohort of HCRN GU14-188.](#)

Genitourinary Cancer—Kidney and Bladder - Bladder Cancer
Authors: **Christopher J. Hoimes**, Nabil Adra, Mark T. Fleming, Hristos Z. Kaimakliotis, Joel Picus, Zachary L Smith, Radhika Walling, Edouard John Trabulsi, Jean H. Hoffman-Censits, Michael O. Koch, Clint Cary, Robert Abouassaly, Cheryl Eitman, **Pingfu Fu**, Gordon Goolamier, Adam C Calaway, **Lee Evan Ponsky**, William Kevin Kelly; Duke Cancer Institute, Durham, NC; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Virginia Oncology Associates, US Oncology Research, Norfolk, VA; Indiana University Simon Cancer Center, Indianapolis, IN; Washington University in St. Louis School of Medicine, St. Louis, MO; Washington University School of Medicine, St Louis, MO; Community Cancer Center, Indianapolis, IN; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Glickman Urology and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Seidman Cancer Center at University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

[\(6074\) Computerized features of spatial arrangement of tumor-infiltrating lymphocytes from H&E images predicts survival and response to checkpoint inhibitors in gynecologic cancers.](#)

Gynecologic Cancer – Ovarian Cancer
Authors: Sepideh Azarianpour Esfahani, Germán Corredor, Kaustav Bera, **PingFu Fu**, Amy Joehlin-Price, Haider Mahdi, **Anant Madabhushi**; Case Western Reserve University, Cleveland Heights, OH; Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

[\(6093\) Genomic and transcriptomic profiles of gynecologic neuroendocrine carcinoma are distinct from pulmonary neuroendocrine small cell carcinoma.](#)

Gynecologic Cancer – Other Cancer
Authors: **Haider Mahdi**, Amy Joehlin-Price, **Afshin Dowlati**, **Ata Abbas**; Cleveland Clinic, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH

[\(6559\) Computerized features of spatial interplay of tumor-infiltrating lymphocytes predict disease recurrence in p16+ oropharyngeal squamous cell carcinoma: A multisite validation study.](#)

Head and Neck Cancer – Biomarkers/Epidemiology/Outcomes
Authors: Germán Corredor, Cheng Lu, Can Koyuncu, Kaustav Bera, Paula Toro, **Pingfu Fu**, Shlomo A.

Cancer Center members indicated in **BOLD**

Koyfman, Deborah Chute, **David J. Adelstein**, Wade Thorstad, Justin A. Bishop, Farhoud Faraji, James Lewis Jr., **Anant Madabhushi**; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Wash U in St. Louis, St. Louis, MO; UT Southwestern Medical Center, Dallas, TX; University of California, San Diego, San Diego, CA; Vanderbilt University Medical Center, Nashville, TN; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

[\(6566\) Combination of tumor multinucleation and spatial arrangement of tumor-infiltrating lymphocytes to predict overall survival in oropharyngeal squamous cell carcinoma: A multisite study.](#)

Head and Neck Cancer – Biomarkers/Epidemiology/Outcomes

Authors: Can Koyuncu, Germán Corredor, Cheng Lu, Paula Toro, Kaustav Bera, **Pingfu Fu**, Shlomo A. Koyfman, Deborah Chute, **David J. Adelstein**, Wade Thorstad, Justin A. Bishop, Farhoud Faraji, James S. Lewis, **Anant Madabhushi**; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Washington University in St. Louis, St. Louis, MO; The Johns Hopkins University, Baltimore, MD; University of California, San Diego, San Diego, CA; Dept of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN; Case Western Reserve University, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

[\(7027\) Effect of shorter time to treatment on survival in rural patients with breast cancer.](#)

Health Services Research and Quality Improvement – Disparities/Access to Care

Authors: Suneel Deepak Kamath, Wei Wei, Katherine Tullio, **Gregory S. Cooper**, **Alok A. Khorana**; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic- Taussig Cancer Institute, Cleveland, OH

[\(7526\) Glasdegib in combination with azacitidine \(AZA\) in patients \(pts\) with untreated higher-risk myelodysplastic syndromes \(MDS\), acute myeloid leukemia \(AML\) and chronic myelomonocytic leukemia \(CMML\): Effects on marrow recovery and transfusion indepe](#)

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft – Acute Leukemia

Authors: Amer Methqal Zeidan, Michael Schuster, Magalie Joris, Jurgen Krauter, Johan Maertens, Emmanuel Gyan, Tibor Kovacovics, Amit Verma, Paresh Vyas, Eunice S. Wang, Wendy Ma, Mirjana Zeremski, Art Kudla, Geoffrey Chan, **Mikael A. Sekeres**; Yale University School of Medicine and Yale Cancer Center, New Haven, CT; Stony Brook Medicine, Stony Brook, NY; CHU Amiens-Picardie, Salouel, France; Medizinische Klinikum Braunschweig GmbH, Braunschweig, Germany; UZ Leuven, Leuven, Belgium; CHU de Tours-Hôpital Bretonneau, Tours Cedex, France; Huntsman Cancer Institute, Salt Lake City, UT; Montefiore Medical Center, Bronx, NY; University of Oxford and Oxford University Hospitals, Oxford, United Kingdom; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Pfizer Oncology, New York, NY; Pfizer Inc, New York, NY; Pfizer, New York, NY; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

[\(7556\) Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.](#)

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft - Myelodysplastic Syndromes (MDS)

Authors: Ehab L. Atallah, Samer K. Khaled, Brenda W. Cooper, Erica D. Warlick, David A. Ramies, Joanne Li, Riccardo Spezia, Silvia Mappa, Michael Kenneth Keng; Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; Hematologic Malignancies Program, University Hospitals Seidman Cancer

Cancer Center members indicated in **BOLD**

Center and Case Western Reserve University, Cleveland, OH; Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN; MEI Pharma, Inc, San Diego, CA; Helsinn Healthcare SA, Lugano, Switzerland; Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA

[\(8043\) Outcomes of Burkitt lymphoma \(BL\) managed in academic \(Acad\) or community \(Comm\) centers: real-world evidence \(RWE\) from 30 US sites.](#)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Non-Hodgkin Lymphoma
Authors: Adam J. Olszewski, Izidore S. Lossos, Andrzej Stadnik, Stephen Douglas Smith, **Deepa Jagadeesh**, Seo-Hyun Kim, Tyce Jovelle Phillips, Seema Naik, Tatyana Feldman, Nishitha Reddy, Suchitra Sundaram, Seth Maliske, Vaishalee Padgaonkar Kenkre, Narendranath Epperla, Malvi Savani, Craig Portell, Neil Palmisiano, Andreas Kirschmer Klein, Andrew M. Evens, Burkitt Lymphoma RWE Cohort Investigators; Rhode Island Hospital-The Warren Alpert Medical School of Brown University, Providence, RI; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Oregon Health & Science University, Portland, OR; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Rush University, Chicago, IL; University of Michigan, Ann Arbor, MI; Penn State Cancer Institute, Hershey, PA; John Theurer Cancer Center, Hackensack, NJ; Vanderbilt University Medical Center, Nashville, TN; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Aspirus Wausau Hospital Regional Cancer Center, Wausau, WI; University of Wisconsin, Madison, WI; The Ohio State University, Columbus, OH; University of Minnesota, Minneapolis, MN; University of Virginia, Charlottesville, VA; Thomas Jefferson University Hospital, Philadelphia, PA; Tufts Medical Center, Boston, MA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

[\(9027\) Base excision repair \(BER\) inhibitor TRC 102 \(Methoxyamine\) combined with pemetrexed \(PEM\)-based chemo-radiation \(CRT\) for locally advanced non-squamous non-small cell lung cancer \(NS-NSCLC\): Results of a phase I trial.](#)

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Local-Regional Non-Small Cell Lung Cancer

Authors: Tithi Biswas, **Afshin Dowlati**, Charles Kunos, **John Pink**, **Nancy Oleinick**, Shakun M. Malik, **Pingfu Fu**, **Debora S. Bruno**, **David Lawrence Bajor**, **Monaliben Patel**, **Mitchell Machtay**; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; National Cancer Institute, Rockville, MD; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH

[\(10124\) A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs.](#)

Symptoms and Survivorship - Palliative Care and Symptom Management

Authors: Amin Firoozmand, Naveed Ali, Nausheen Ahmed, **Pingfu Fu**, Shufen Cao, George Brown, Hannah Schmikla, **James Joseph Driscoll**, **Timothy O' Brien**, **Paolo Fabrizio Caimi**, **Marcos J.G. De Lima**, **Ehsan Malek**; University Hospitals Seidman Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University Seidman Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Department of Biostats and Epidemiology, Case Western Reserve University, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

Cancer Center members indicated in **BOLD**

[\(11561\) Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma.](#)

Sarcoma – Soft Tissue

Authors: Mark Agulnik, Steven Ian Robinson, Scott H. Okuno, Brittany Siontis, Steven Attia, Masha Kocherginsky, Mohammed M. Milhem, Varun Monga, Sant P. Chawla, Peter John Oppelt, Angela C. Hirbe, Brian Andrew Van Tine; Northwestern University, Feinberg School of Medicine, Chicago, IL; Mayo Clinic, Rochester, MN; University of Michigan, Ann Arbor, MI; Mayo Clinic, Jacksonville, FL; Northwestern University Feinberg School of Medicine, Chicago, IL; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA; University of Iowa Hospitals and Clinics, Iowa City, IA; Sarcoma Oncology Research Center, Santa Monica, CA; University Hospital Case Medical Center, Cleveland, OH; Washington University in St. Louis, St. Louis, MO; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO

[\(12123\) Video conference intervention for distance caregivers \(DCGs\) of patients with cancer: Improving psychological outcomes.](#)

Symptoms and Survivorship – Psychosocial and Communication Research

Authors: **Sara L Douglas**, Polly Mazanec, Amy R Lipson, Eric Blackstone, Kim Day, **David Lawrence Bajor**, **Smitha S. Krishnamurthi**; Case Western Reserve University and Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Case Western Reserve University-School of Nursing, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

[\(TPS3652\) SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – New. Targets and New Technologies (non-IO)

Authors: Amita Patnaik, Funda Meric-Bernstam, Caio Max Sao Pedro Rocha Lima, Francisco Robert, **Afshin Dowlati**, Hedy L. Kindler, Diwakar Davar, Steven Francis Powell, Phillip M. Garfin, Ani Sarkis Balmanoukian; START, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; NRG Oncology, and Wake Forest University Baptist Medical Center, Winston-Salem, NC; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University of Chicago, Chicago, IL; University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA; Sanford Health, Sioux Falls, SD; Seattle Genetics, Bothell, WA; The Angeles Clinic and Research Institute, Los Angeles, CA

[\(TPS4671\) Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma \(PDAC\).](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary - Pancreatic Cancer

Authors: Andrew L. Coveler, **David Lawrence Bajor**, Ashiq Masood, Emrullah Yilmaz, Anthony Frank Shields, Milind M. Javle, Ravi Kumar Paluri, Gina M. Vaccaro, Mark Zalupski, Juneko E. Grilley-Olson, Hedy L. Kindler, Michael W. Schmitt, Martin Gutierrez; Seattle Cancer Care Alliance/University of Washington, Seattle, WA; Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH; Rush University, Chicago, IL; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Karmanos Cancer Institute, Wayne State University, Detroit, MI; MD Anderson Cancer Center, Houston, TX; University of Alabama at Birmingham, Birmingham, AL; Providence Cancer Institute, Portland, OR; University of Michigan, Ann Arbor, MI; UNC Lineberger Comprehensive Cancer Center/University of North Carolina Chapel Hill, Chapel Hill, NC; University of Chicago, Chicago, IL; Seattle Genetics, Inc., Bothell, WA; Hackensack University Medical Center, Hackensack, NJ

Cancer Center members indicated in **BOLD**

[\(TPS8068\) Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma \(Trial in Progress\).](#)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia – Hodgkin Lymphoma
Authors: Judah D. Friedman, Hun Ju Lee, Linda Ho, Ian Flinn; University Hospitals Seidman Cancer Center, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; Seattle Genetics, Inc., Bothell, WA; Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN

[\(TPS9080\) Phase I study of AMG 757, a half-life extended bispecific T-cell engager \(HLE BiTE immune therapy\) targeting DLL3, in patients with small cell lung cancer \(SCLC\).](#)

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Small Cell Lung Cancer
Authors: Taofeek Kunle Owonikoko, Hossein Borghaei, Stéphane Champiat, Luis G. Paz-Ares, Ramaswamy Govindan, Michael J. Boyer, Melissa Lynne Johnson, Hibiki Udagawa, Horst-Dieter Hummel, Ravi Salgia, Fiona Helen Blackhall, Rene J. Boosman, Wei-Chu Victoria Lai, **Afshin Dowlati**, Everett E. Vokes, Christine L. Hann, Anne C. Chiang, Marichu Endraca, Neelesh Soman, Marie-Anne Damiette Smit; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Fox Chase Cancer Center, Philadelphia, PA; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif, France; Hospital Universitario 12 de Octubre, H120H120-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & Ciberonc, Madrid, Spain; Divisions of Hematology and Oncology, Washington University Medical School, St. Louis, MO; Chris O'Brien Lifecare, Camperdown, NSW, Australia; Lung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA; Department of Medical Oncology, The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center, New York, NY; Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH; University of Chicago Medicine and Biological Sciences, Chicago, IL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT; Translational Medicine, Amgen Inc., Thousand Oaks, CA

[\(TPS12129\) Use of simulation for training family caregivers of patients receiving radiation therapy. Symptoms and Survivorship – Psychosocial and Communication Research](#)

Authors: **Susan R Mazanec**, Eric Blackstone, Jennifer Anne Dorth, Kate Sandstrom, Celeste Alfes, Nicholas K Schiltz, Mendel E Singer, Rod Rezaee, **Barbara J. Daly**; Case Western Reserve Univ, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Epidemiology & Biostatistics, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH

Publication Only Abstracts

[\(e12547\) Radiation therapy following breast conserving surgery \(BCS\) in women with early-stage breast cancer and low oncotype scores](#)

Breast Cancer—Local/Regional/Adjuvant—Adjuvant Therapy
Authors: Nicholas Damico, Michael Kharouta, **Janice A. Lyons**, Eleanor Elizabeth Harris; University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH

Cancer Center members indicated in **BOLD**

[\(e14103\) Pilot study for the use of wearable devices for patients undergoing oral chemotherapy](#)

Care Delivery and Regulatory Policy—Digital Technology/Therapeutics

Authors: **Monaliben Patel**, Matthew M. Cooney, **Paolo Fabrizio Caimi**, Rory Eric Randall, **Leland L. Metheny**, **Prateek Mendiratta**, **Debora S. Bruno**, **Paula Silverman**; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, OH; University Hospitals of Seidman Cancer Center/Case Comprehensive Cancer Center, Cleveland, OH; The MetroHealth System, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH

[\(e15000\) Risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors](#)

Developmental Therapeutics—Immunotherapy—Antibodies

Authors: Tariq Zuheir Kewan, Ramsha Ahmed, Sura Alqaisi, Fahrettin Covut, Monica Flores, Arslan Babar, Abdo S. Haddad, Hamed Daw; Department of Medicine, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

[\(e15096\) Neurotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis](#)

Developmental Therapeutics-Immunotherapy—Immune Checkpoint Inhibitors

Authors: Muhammad Zain Farooq, Sheeba Habeeb Ba Aqeel, Prasanth Lingamaneni, Shristi Upadhyay Banskota, Rayli Pichardo, Mahrukh Siddiqui, Trilok Shrivastava, Ankit Mangla; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Hospital of Cook County, Chicago, IL; Amita Saint Joseph Hospital, Chicago, IL; University Hospitals-Seidman Cancer Center, Cleveland, OH

[\(e15100\) Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data](#)

Developmental Therapeutics-Immunotherapy—Immune Checkpoint Inhibitors

Authors: Prantesh Jain, Jahir Gutierrez Bugarin, Avirup Guha, Chhavi Jain, Tingke Shen, Ilya Stanevich, Seunghee P Margevicius, **Pingfu Fu**, Fang Liu, Vipani Nikore, Ankit Mangla, **Marcos J.G. De Lima**, Vamsidhar Velcheti, **Jill Barnholtz-Sloan**, **Afshin Dowlati**; University Hospitals-Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; University Hospitals-Seidman Cancer Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH; University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH; NYU Langone, Perlmutter Cancer Center, New York, NY; Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

[\(e15131\) Cardiotoxicity associated with immune checkpoint inhibitors: A systemic review and meta-analysis](#)

Developmental Therapeutics-Immunotherapy—Immune Checkpoint Inhibitors

Authors: Sheeba Habeeb Ba Aqeel, Prasanth Lingamaneni, Shristi Upadhyay Banskota, Muhammad Zain Farooq, Rayli Pichardo, Ishaan Vohra, Ankit Mangla; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Hospital of Cook County, Chicago, IL; University Hospitals-Seidman Cancer Center, Cleveland, OH

Cancer Center members indicated in **BOLD**

[\(e15631\) Bevacizumab induced proteinuria and hypertension: A comparative analysis of anti-hypertensives utilized within a single institution](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology—Pharmacology
Authors: Marwah Wafa Farooqui, Nicholas Gustafson, Nisha Patel, Erika Danelski, Tirth Patel, Krishnan Srinivasan, Amy Stein, Masood Ghouse; University Hospitals-Cleveland Medical Center Regional, Cleveland, OH; Franciscan Health, Olympia Fields, IL; Midwestern University, Downers Grove, IL; Midwestern University, Glendale, AZ

[\(e16725\) Utilization of imaging in pancreatic adenocarcinoma patients status post whipple procedure](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary—Pancreatic Cancer
Authors: Neal Shah, Ruchika Podury, Elias Kikano, Daniel Arnold Smith, Nikhil H. Ramaiya, Sree Harsha Tirumani; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

[\(e16730\) Clinical trials in pancreatic cancer: A comprehensive analysis](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary—Pancreatic Cancer
Authors: Erryk Stephan Katayama, Jonathan J. Hue, **David Lawrence Bajor**, Lee Mayer Ocuin, John Brian Ammori, **Jeffrey Hardacre**, **Jordan Michael Winter**; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Atrium Health, Concord, NC; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

[\(e17007\) Emerging clinical phenotype of bone metastatic urothelial cancer \(mUC\): Association of early osseous metastases \(EOM\) and outcomes](#)

Genitourinary Cancer – Kidney and Bladder—Bladder Cancer
Authors: Ariel Ann Nelson, Robert Cronk, Aniko Szabo, Emily Lemke, Thomas A. Giever, John D. Burfeind, Deepak Kilari, Matthew John Riese, Kathryn A. Bylow, Leonidas Nikolaos Diamantopoulos, Ali Raza Khaki, Behdash Nezami, **Gregory MacLennan**, Mary Ann Draves, Gordon Goolamier, Samantha Rosey, Adam Calaway, Petros Grivas, **Lee Evan Ponsky**, **Christopher J. Hoimes**; Medical College of Wisconsin, Milwaukee, WI; University of Washington, Seattle, WA; Case Western Reserve University-Department of Pathology, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

[\(e17050\) Impact of preoperative neutrophil to lymphocyte ratio \(NLR\) and platelet to lymphocyte ratio \(PLR\) on overall survival or recurrence free survival in muscle-invasive bladder cancer at cystectomy](#)

Genitourinary Cancer – Kidney and Bladder—Bladder Cancer
Authors: Scott Dawsey, Iris Yeong- Fung Sheng, Moshe Chaim Ornstein, Wei Wei, **Byron H Lee**, **Omar Y. Mian**, Brian I. Rini, **Jorge A. Garcia**, **Timothy D. Gilligan**, **Shilpa Gupta**; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Cancer Center, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Dept. of Radiation Oncology, Dept. of Translational Hematology Oncology Research, Cleveland, OH

[\(e17510\) Comorbidity burden in prostate cancer patients by ESRD status](#)

Genitourinary Cancer—Prostate, Testicular, and Penile—Biomarkers/Epidemiology/Outcomes
Authors: Nagaraju Sarabu, Weichuan Dong, Austin Fernstrum, Al Ray, **Lee Evan Ponsky**, **Siran M. Koroukian**; University Hospitals of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH

Cancer Center members indicated in **BOLD**

[\(e17513\) Prostate cancer outcomes by ESRD status](#)

Genitourinary Cancer—Prostate, Testicular, and Penile—Biomarkers/Epidemiology/Outcomes

Authors: Nagaraju Sarabu, Weichuan Dong, Al Ray, Austin Fernstrum, **Lee Evan Ponsky, Siran M.**

Koroukian; University Hospitals of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH

[\(e19525\) Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center](#)

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft—Allogeneic Stem Cell Transplantation

Authors: Mahmoud Gaballa, Albert Jang, Hussein Hamad, Shaun Bulsara, Meng-Fen Wu, George Carrum, Carlos Almeida Ramos, Rammurti Kamble, LaQuisa Hill, Sai Ravi Pingali, Ngoc Vu, Audrey Scholoff, Gloria Obi, Helen E. Heslop, Premal D. Lulla; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Department of Medicine, Tulane University School of Medicine, New Orleans, LA; University Hospitals of Cleveland, Samaritan Medical Center, Case Western University, Cleveland, OH

[\(e20031\) Prognostic value of baseline elevated red cell distribution width in DLBCL](#)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia—Non-Hodgkin Lymphoma

Authors: Akiva Diamond, Kirsten M Boughan, **Marcos J.G. De Lima, Paolo Fabrizio Caimi**; University Hospitals Cleveland Medical Center and Case Comprehensive Cancer Center, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH

[\(e20054\) Survival from time of transformation in patients with transformed lymphoma at time of diagnosis](#)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia—Non-Hodgkin Lymphoma

Authors: Alaina Kelly, Kirsten M Boughan, Patricio Rojas, Nausheen Ahmad, Akiva Diamond, **Marcos J.G. De Lima, Paolo Fabrizio Caimi**; Case Western Reserve University School of Medicine, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; Pontificia Universidad Catolica de Chile, Santiago, Chile; University Hospitals Cleveland Medical Center, Cleveland, OH

[\(e21680\) Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer \(NSCLC\) patients](#)

Lung Cancer—Non-Small Cell Metastatic—Metastatic Non-Small Cell Lung Cancer

Authors: **Afshin Dowlati**, Chandra Prakash Belani, George R. Simon, Heman Chao, Sarina Anne Piha-Paul; University Hospitals Case Medical Center, Cleveland, OH; Penn State Cancer Institute, Hershey, PA; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Helix BioPharma Corp, Aurora, ON, Canada; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX

[\(e23000\) HemeOncoPoeisis: A fellow's perspective on training](#)

Professional Development and Education Advances—Education Research

Authors: Marwah Wafa Farooqui, Stephen Simeone, Yatri Desai, Krishnan Srinivasan, Masood Ghouse; University Hospitals-Cleveland Medical Center Regional, Cleveland, OH; Midwestern University, Downers Grove, IL; Franciscan Health, Olympia Fields, IL

Cancer Center members indicated in **BOLD**

[\(e24052\) Improve, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-hispanic white breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics](#)

Symptoms and Survivorship—Health Promotion

Authors: **Cynthia Owusu**, **Nora Nock**, Paul F. Hergenroeder, Kris Austin, Beth Bennett, Stephen Cerne, **Halle C. F. Moore**, Jean Petkac, **Mark D. Schluchter**, Kathryn H. Schmitz, Monica Webb-Hooper, Leonard Wimbley, Sarah Coccia, Caitlin Nagy, **Nathan A. Berger**; Case Western Reserve University School of Medicine, Cleveland, OH; MetroHealth Medical Center, Cleveland, OH; The Gathering Place, Beachwood, OH; Cleveland Clinic, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University of Pennsylvania, Philadelphia, PA; Case Western Reserve Univ, Cleveland, OH

[\(e24176\) Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research \(CCDR\) Protocol - A191402CD - A Cluster-Randomized Trial](#)

Symptoms and Survivorship—Psychosocial and Communication Research

Authors: Jon Charles Tilburt, Joel E Pacyna, Daniel G. Petereit, Judith Salmon Kaur, Bruce D. Rapkin, Robert Grubb, George J. Chang, Michael J. Morris, Evan Kovac, Jeff A. Sloan, Ethan M. Basch, Elizabeth M. Storrnick, David Zahrieh, Amylou C. Dueck, Electra D. Paskett, Jan C. Buckner, Victor Montori, Domnick L Frosch, Robert Joseph Volk, Simon P. Kim; Mayo Clinic, Rochester, MN; Rapid City Reg Hosp Cancer Care Inst, Rapid City, SD; Mayo Clinic, Jacksonville, FL; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY; Medical University of South Carolina, Charleston, SC; The University of Texas MD Anderson Cancer Center, Houston, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic, Cleveland, OH; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Mayo Clinic Rochester, Rochester, MN; Mayo Clinic, Scottsdale, AZ; The Ohio State University, Columbus, OH; Gordon and Betty Moore Foundation, Palo Alto, CA; University of Texas MD Anderson Cancer Center, Houston, TX; University Hospitals Cleveland Medical Center, Cleveland, OH

[\(e24198\) Video conferencing long distance caregivers during oncology appointments: Implications for clinical practice](#)

Symptoms and Survivorship—Psychosocial and Communication Research

Authors: Eric Blackstone, Sumin Park, **Smitha S. Krishnamurthi**, **David Lawrence Bajor**, Polly Mazanec, Kim Day, **Sara L Douglas**; Case Western Reserve University, Cleveland, OH; Cleveland Clinic Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve University and Case Comprehensive Cancer Center, Cleveland, OH